BioLLM Wiki β€Ί Disease Indications

Breast Cancer

The papers study breast cancer, including hormone-receptor-defined HER2-negative disease and triple-negative breast cancer, as well as metastatic and advanced breast cancer. They address treatment resistance, chemotherapy and combination therapies, nanoparticle or albumin-bound drug delivery, antitumor immune responses, treatment-related pain, and molecular mechanisms. The studies use patient cohorts and clinical trials, breast cancer cell lines and primary cells, mouse models, DCE-MRI radiomics with machine-learning models, and molecular analyses to assess treatment response, survival, metastasis prediction, and adverse effects.

Papers
4,982
Jan 2024 – Aug 2026
2024 share
4.28%
of the month's papers, on average
2025 share
4.36%
of the month's papers, on average
2026 share
3.95%
of the month's papers, on average
Change
β–Ό -7.7%
2024 β†’ 2026, relative

Share of papers by month

Peak 5.14% in Aug 2025. Month-by-month values and sub-terms are on Keyword Trends.

Jan 2024Aug 2026

Nanomedicine and combination therapy

Several studies developed nanoparticles, liposomes, metal-organic frameworks, lignin-based nanocarriers, or niosomes for delivery of doxorubicin, mitoxantrone, or phytochemical agents while addressing drug resistance, systemic toxicity, or tumor targeting. Nanoparticle formulations combining doxorubicin with sanguinarine were tested in parental and Adriamycin-resistant MCF-7 cells, PEGylated liposomes co-loaded doxorubicin with miR-145 mimics for in-vitro testing in MDA-MB-231 cells, and MUC-1 aptamer-conjugated Janus silver–mesoporous-silica nanoparticles combined doxorubicin delivery with P-glycoprotein antisense-mediated MDR suppression and photothermal therapy in drug-resistant MCF-7/ADR cells (38180322; 39101839; 39454415). Other platforms used redox/pH-responsive metal-organic frameworks for mitoxantrone, lignin nanoparticles with pH- and glutathione-responsive doxorubicin release, and niosomes for synergistic doxorubicin–piperine delivery and reduced expression of cancer-stem-cell-associated markers (41137753; 41874975; 40782357).

πŸ“„ Drug development and industrial pharmacy β†—πŸ“„ Journal of liposome research β†—πŸ“„ Biomaterials advances β†—πŸ“„ ACS applied materials & interfaces β†—πŸ“„ ACS applied bio materials β†—πŸ“„ Pharmaceutical development and technology β†—

Resistance and molecular targets

The studies investigate molecular determinants of resistance to endocrine therapy, CDK4/6 inhibitors, mTOR inhibitors, and cytotoxic drugs. NanoCurcumin was evaluated with tamoxifen in ER-positive disease in relation to MALAT1 and other long noncoding RNAs, while PCK1 was linked to Cyclin D3 and CDK4/6-inhibitor resistance and PMEPA1 was identified in everolimus- and ridaforolimus-resistant TNBC models with persistent mTOR signaling, PI3K/AKT activation, and TGF-Ξ²/KRAS signaling (41031251; 41748011; 41819443). Other work assessed tumor pharmacodynamics of the PARP inhibitor talazoparib in BRCA-mutated tumors and showed that HIV-protease inhibitors enhanced carfilzomib cytotoxicity in TNBC cells; lopinavir also increased intracellular carfilzomib availability and induced endoplasmic-reticulum stress and a pro-apoptotic unfolded protein response (38010394; 38969867).

πŸ“„ BioMed research international β†—πŸ“„ Cancer letters β†—πŸ“„ Biochemical pharmacology β†—πŸ“„ Cancer chemotherapy and pharmacology β†—πŸ“„ British journal of cancer β†—

Imaging and computational diagnosis

Machine-learning and radiomic methods were applied to non-sentinel lymph-node metastasis prediction, mammographic interpretation, and reducing unnecessary biopsies. A retrospective two-hospital DCE-MRI study combined radiomic scores with clinical factors to predict non-sentinel lymph-node metastasis in Chinese breast cancer patients with one or two positive sentinel lymph nodes, while radiomics, deep learning, and information fusion were used to evaluate BI-RADS 4 mammographic calcifications and reduce invasive biopsies of benign calcifications (38490840; 39633212). Other studies used global mammographic radiomic features to identify normal cases that radiology trainees found hardest to interpret, MOF-based electrochemical and colorimetric sensing to quantify HER-2, and 68Ga-FAPI PET/CT combined with MAMMI PET to assess residual tumor after neoadjuvant chemotherapy (39407048; 40712488; 41391941).

πŸ“„ Academic radiology β†—πŸ“„ Journal of imaging informatics in medicine β†—πŸ“„ Journal of imaging informatics in medicine β†—πŸ“„ Biosensors & bioelectronics β†—πŸ“„ Cancer biotherapy & radiopharmaceuticals β†—

Local treatment and survivorship

Studies examined local treatments and treatment-related outcomes. In a bilateral TNBC mouse model, cryoablation of the primary tumor was examined for systemic immune effects in distant tumors, while a prospective randomized study compared intraoperative ultrasound with conventional breast-conserving surgery for achieving negative margins (39703517; 38901438). Clinical radiation studies evaluated hypofractionated regional nodal irradiation and single-fraction high-gradient partial-breast irradiation, while other studies evaluated moderate-intensity aerobic exercise in postmenopausal women receiving aromatase inhibitors and described very late radiation-induced brachial plexopathy after breast-cancer radiotherapy (40311918; 40912507; 40035875; 39348524).

πŸ“„ Frontiers in immunology β†—πŸ“„ Ultraschall in der Medizin (Stuttgart, Germany : 1980) β†—πŸ“„ Practical radiation oncology β†—πŸ“„ International journal of radiation oncology, biology, physics β†—πŸ“„ Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer β†—πŸ“„ Physiotherapy theory and practice β†—

Written by gpt-5.6-luna from 96 of this keyword's papers, a few from every whole month through Aug 2026; every paragraph was checked against the abstracts it cites. A paper counts for the keyword when its title, abstract, keywords or MeSH headings match the keyword's terms. Not medical advice; see the Disclaimer.